版本:
中国

BRIEF-Nicox gets letter from FDA related to GMP on NDA for AC-170

Oct 10 Nicox Sa

* Nicox receives complete response letter from the FDA related to GMP on NDA for ac-170

* Nicox sa - crl did not include any concerns related to finished product manufacturing facility

* Nicox sa - since receipt of crl, nicox has been contacting its suppliers to assess timeline for api manufacturer to address fda's concerns

* Nicox sa - once issues have been addressed, nicox will then resubmit ac-170 nda

* Nicox sa - fda's stated reason for crl pertains solely to a good manufacturing practice (gmp) inspection at a third party facility Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐